The purpose is to give patients receiving intravenous infliximab a new subcutaneous option for convenience and improved quality of life.
Treatment for Crohn's disease and UC varies based on severity; mesalamine for mild cases, corticosteroids for moderate to severe, aiming to avoid long-term steroid use.
Collection
[
|
...
]